Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $66.6 million.

  • Trinity Biotech's Non-Current Assets rose 3775.2% to $66.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $66.6 million, marking a year-over-year increase of 3775.2%. This contributed to the annual value of $62.2 million for FY2024, which is 20482.49% up from last year.
  • As of Q2 2025, Trinity Biotech's Non-Current Assets stood at $66.6 million, which was up 3775.2% from $62.2 million recorded in Q4 2024.
  • In the past 5 years, Trinity Biotech's Non-Current Assets registered a high of $66.6 million during Q2 2025, and its lowest value of $19.1 million during Q2 2023.
  • Over the past 5 years, Trinity Biotech's median Non-Current Assets value was $46.2 million (recorded in 2021), while the average stood at $43.4 million.
  • In the last 5 years, Trinity Biotech's Non-Current Assets crashed by 6178.26% in 2023 and then soared by 20482.49% in 2024.
  • Over the past 5 years, Trinity Biotech's Non-Current Assets (Quarter) stood at $46.2 million in 2021, then dropped by 1.67% to $45.4 million in 2022, then plummeted by 55.11% to $20.4 million in 2023, then soared by 204.82% to $62.2 million in 2024, then increased by 7.18% to $66.6 million in 2025.
  • Its last three reported values are $66.6 million in Q2 2025, $62.2 million for Q4 2024, and $51.4 million during Q3 2024.